Preparing for long-acting PrEP delivery: building on lessons from oral PrEP

被引:16
|
作者
Celum, Connie [1 ,2 ,3 ,4 ]
Grinsztejn, Beatriz [5 ]
Ngure, Kenneth [6 ]
机构
[1] Harborview Med Ctr, POB 359927,325 Ninth Ave, Seattle, WA 98104 USA
[2] Univ Washington, Dept Global Hlth, Seattle, WA USA
[3] Univ Washington, Dept Med, Seattle, WA USA
[4] Univ Washington, Dept Epidemiol, Seattle, WA USA
[5] Evandro Chagas Natl Inst Infect Dis Fiocruz, Rio de Janeiro, Brazil
[6] Jomo Kenyatta Univ Agr & Technol, Sch Publ Hlth, Nairobi, Kenya
关键词
adherence; delivery; HIV pre-exposure prophylaxis; lessons; long-acting; persistence; HIV PREEXPOSURE PROPHYLAXIS; ANTIRETROVIRAL PROPHYLAXIS; PREVENTION; INFECTION; ADHERENCE; TENOFOVIR; CARE; DISCONTINUATION; MEN; CLINICS;
D O I
10.1002/jia2.26103
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Introduction With recent approvals of long-acting (LA) HIV pre-exposure prophylaxis (PrEP) in the form of injectable cabotegravir and the dapivirine ring, programmes need to consider how to optimize the delivery of PrEP methods, including by leveraging lessons from the past decade of oral PrEP delivery.Discussion Framed around differentiated service delivery building blocks, the major considerations for the delivery of LA PrEP are how to reach the populations who would most benefit from PrEP, where to locate PrEP services, how to reduce the user burden of accessing and continuing with PrEP, and how to integrate PrEP with other services. Demand creation for LA PrEP and education about new LA PrEP options should be co-developed with communities and be positively framed. Client-facing clinical decision support tools provide information about HIV prevention and PrEP options in non-technical ways and can support their informed decision-making about PrEP. Training for providers is needed to increase their ability to ask about sexual and drug use behaviours in a non-judgmental and comfortable manner as part of risk assessment, discuss harm reduction strategies and counsel about available PrEP options that fit clients' circumstances and needs. PrEP adherence support should include supportive counselling and be tailored to address an individual's particular barriers and needs. Reminders through text messaging or calls can foster PrEP persistence, given the narrow the window around dosing for injectable cabotegravir. Strategies are needed to expand PrEP delivery options, including telePrEP, pharmacy-based PrEP, key population-led services and mobile venues. Integrated delivery models are needed which include sexually transmitted infection testing and treatment, contraception for cis-women not desiring to become pregnant, PrEP for pregnant women in high HIV prevalence settings, and gender-affirming hormones and support for transgender persons.Conclusions The outcome of expanding PrEP options through LA PrEP formulations is to increase PrEP coverage, adherence, persistence and effectiveness by offering a choice of PrEP that meets the needs of persons who would benefit from PrEP. The lessons learned from the delivery of oral PrEP about demand creation, informed client decision-making, provider training, adherence support and service delivery model are relevant to the delivery of LA PrEP and integration with other services.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Preparing for long-acting PrEP delivery: provider preferences for the provision of long-acting PrEP differ between MSM and heterosexual individuals in Europe
    Zimmermann, Hanne
    Wang, Haoyi
    Kolstee, Johann
    Lozano, Alejandro Adriaque
    Schroeder, Melanie
    Appiah, Ama
    Milinkovic, Ana
    Sakar, Supriya
    Jonas, Kai
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 : 31 - 32
  • [2] Long-acting injectable PrEP
    Harris, Philippa
    LANCET HIV, 2020, 7 (08): : E532 - E532
  • [3] PrEParing for long-acting injectable PrEP in the South: perspectives from healthcare providers in Georgia
    Xavier Hall, Casey D.
    Smith, Justin C.
    Driggers, Robert A.
    Stoller, Bethany
    Khan, Zara
    Li, Jingjing
    Ignatius, Elisa H.
    Siegler, Aaron J.
    AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV, 2021, 33 (06): : 706 - 711
  • [4] Long-Acting PrEP Shows Promise
    Kuehn, Bridget M.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 324 (07): : 621 - 621
  • [5] Microarray Patches (MAPs) for Delivery of Long-acting HIV PrEP and Contraception
    Rein-Weston, Annie
    Kilbourne-Brook, Maggie
    Creelman, Ben
    Saxon, Gene
    Frivold, Collrane
    Delarosa, Jaclyn
    Moyo, Yolanda
    Mukabi, James
    Kariithi, Edward
    Katuntu, David
    Jarrahian, Courtney
    Donnellly, Ryan
    Zehrung, Darin
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2018, 34 : 222 - 222
  • [6] Considerable interest in long-acting PrEP approaches among PrEP-users
    Almahfoud, Maher
    Matthews, Hanna
    Weimann, Lukas
    Scheiter, Robin Luca
    Huefner, Anja-Dorothee
    Weichel, Hanna-Marie
    Koch, Till
    Grenz, Marc
    Eckstein, Kai
    Schaefer, Guido
    Pestel, Julia
    Schmiedel, Stefan
    Degen, Olaf
    HIV MEDICINE, 2023, 24 : 71 - 72
  • [7] In PrEP: Long-acting antivirals for HIV prevention
    Sharma, Amit
    CELL HOST & MICROBE, 2022, 30 (02) : 148 - 150
  • [8] Long-acting PrEP prevents HIV in women
    O'Leary, Karen
    NATURE MEDICINE, 2024, 30 (12) : 3393 - 3393
  • [9] Equitable access to long-acting PrEP on the way?
    不详
    LANCET HIV, 2022, 9 (07): : E449 - E449
  • [10] Long-acting cabotegravir pharmacokinetics with and without oral lead-in for HIV PrEP
    Han, Kelong
    Patel, Parul
    McCallister, Scott
    Rinehart, Alex R.
    Gandhi, Yash
    Spreen, William
    Landovitz, Raphael J.
    Delany-Moretlwe, Sinead
    Marzinke, Mark A.
    McKeon, Todd
    Budnik, Piotr
    van Wyk, Jean
    Ford, Susan L.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2024, 68 (06)